BACKGROUND:Amino-terminal pro-B-type natriuretic peptide (NT-proBNP) level is useful to diagnose or exclude acutely decompensated heart failure (ADHF) in dyspnoeic patients presenting to the emergency department (ED). AIM: To evaluate the impact of ED NT-proBNP testing on admission, length of stay (LOS), discharge diagnosis and long-term outcome. METHODS:Dyspnoeic patients were randomized in the ED to NT-proBNP testing. Admission and discharge diagnoses, and outcomes were examined. RESULTS: During 17 months, 470 patients were enrolled and followed for 2.0±1.3 years. ADHF likelihood, determined at study conclusion by validated criteria, established ADHF diagnosis as unlikely in 86 (17%), possible in 120 (24%), and likely in 293 (59%) patients. The respective admission rates in these subgroups were 80, 91, and 96%, regardless of blinding, and 61.9% of blinded vs. 74.5% of unblinded ADHF-likely patients were correctly diagnosed at discharge (p=0.029), with similar LOS. 2-year mortality within subgroups was unaffected by test, but was lower in ADHF-likely patients with NT-proBNP levels below median (5000 pg/ml) compared with those above median (p=0.002). Incidence of recurrent cardiac events tracked NT-proBNP levels. CONCLUSION: ED NT-proBNP testing did not affect admission, LOS, 2-year survival, or recurrent cardiac events among study patients but improved diagnosis at discharge, and allowed risk stratification even within the ADHF-likely group. (ClinicalTrials.gov#NCT00271128).
RCT Entities:
BACKGROUND: Amino-terminal pro-B-type natriuretic peptide (NT-proBNP) level is useful to diagnose or exclude acutely decompensated heart failure (ADHF) in dyspnoeic patients presenting to the emergency department (ED). AIM: To evaluate the impact of ED NT-proBNP testing on admission, length of stay (LOS), discharge diagnosis and long-term outcome. METHODS: Dyspnoeic patients were randomized in the ED to NT-proBNP testing. Admission and discharge diagnoses, and outcomes were examined. RESULTS: During 17 months, 470 patients were enrolled and followed for 2.0±1.3 years. ADHF likelihood, determined at study conclusion by validated criteria, established ADHF diagnosis as unlikely in 86 (17%), possible in 120 (24%), and likely in 293 (59%) patients. The respective admission rates in these subgroups were 80, 91, and 96%, regardless of blinding, and 61.9% of blinded vs. 74.5% of unblinded ADHF-likely patients were correctly diagnosed at discharge (p=0.029), with similar LOS. 2-year mortality within subgroups was unaffected by test, but was lower in ADHF-likely patients with NT-proBNP levels below median (5000 pg/ml) compared with those above median (p=0.002). Incidence of recurrent cardiac events tracked NT-proBNP levels. CONCLUSION: ED NT-proBNP testing did not affect admission, LOS, 2-year survival, or recurrent cardiac events among study patients but improved diagnosis at discharge, and allowed risk stratification even within the ADHF-likely group. (ClinicalTrials.gov#NCT00271128).
Authors: Louisa L Lam; Peter A Cameron; Hans G Schneider; Michael J Abramson; Christian Müller; Henry Krum Journal: Ann Intern Med Date: 2010-12-07 Impact factor: 25.391
Authors: James L Januzzi; Carlos A Camargo; Saif Anwaruddin; Aaron L Baggish; Annabel A Chen; Daniel G Krauser; Roderick Tung; Renee Cameron; J Tobias Nagurney; Claudia U Chae; Donald M Lloyd-Jones; David F Brown; Stacy Foran-Melanson; Patrick M Sluss; Elizabeth Lee-Lewandrowski; Kent B Lewandrowski Journal: Am J Cardiol Date: 2005-04-15 Impact factor: 2.778
Authors: Q Dao; P Krishnaswamy; R Kazanegra; A Harrison; R Amirnovin; L Lenert; P Clopton; J Alberto; P Hlavin; A S Maisel Journal: J Am Coll Cardiol Date: 2001-02 Impact factor: 24.094
Authors: Saif Anwaruddin; Donald M Lloyd-Jones; Aaron Baggish; Annabel Chen; Daniel Krauser; Roderick Tung; Claudia Chae; James L Januzzi Journal: J Am Coll Cardiol Date: 2005-12-09 Impact factor: 24.094
Authors: Hans-Gerhard Schneider; Louisa Lam; Amaali Lokuge; Henry Krum; Matthew T Naughton; Pieter De Villiers Smit; Adam Bystrzycki; David Eccleston; Jacob Federman; Genevieve Flannery; Peter Cameron Journal: Ann Intern Med Date: 2009-03-17 Impact factor: 25.391
Authors: Christian Mueller; André Scholer; Kirsten Laule-Kilian; Benedict Martina; Christian Schindler; Peter Buser; Matthias Pfisterer; André P Perruchoud Journal: N Engl J Med Date: 2004-02-12 Impact factor: 91.245